Increased Red Blood Cell Count in TRT: Risks and Management of This Common Problem for Men on Testosterone Replacement Therapy

By Kyle Kingsley, MD
Medical Director, Lite Medical

Medically Reviewed by Kyle Kingsley, MD, Medical Director, Lite Medical — August 26, 2026

Testosterone replacement therapy (TRT) raises red blood cell production in most men — and for a meaningful subset, it raises it too much. Erythrocytosis, defined as a hematocrit above 54% in men, is the most common lab abnormality seen in TRT patients. It is manageable with the right protocol adjustments, but left unmonitored it carries real risks including blood clots, stroke, and cardiovascular events. Lite Medical physicians monitor hematocrit closely and adjust treatment before problems develop.   All patients should be aware of this risk prior to starting care and we explicitly address this possibility prior to starting TRT with patients.  Generally, this is not an issue with women taking TRT given the significantly lower dose of testosterone taken by women.

What Is Erythrocytosis and Why Does TRT Cause It?

Erythrocytosis means an abnormal increase in the number of red blood cells circulating in your bloodstream. When testosterone levels rise — whether naturally or through TRT — your kidneys respond by producing more erythropoietin (EPO), the hormone that signals your bone marrow to make more red blood cells.

More red blood cells means more oxygen-carrying capacity, which is partly why many men on TRT report feeling more energetic. But there is a ceiling. When hematocrit (the percentage of blood volume made up of red blood cells) climbs too high, blood becomes thicker and more viscous. That thickened blood moves more slowly through vessels, raises clotting risk, and puts additional strain on the heart.

This is not a fringe side effect. Studies show erythrocytosis occurs in approximately 40–50% of men on injectable testosterone over time, and in a smaller but still significant percentage of men on transdermal and other delivery methods. It is predictable, well-understood, and manageable — provided someone is watching your labs.

Risk Factors That Increase Your Likelihood

Not every man on TRT develops clinically significant erythrocytosis. Certain factors raise the risk substantially:

• Injectable testosterone (cypionate or enanthate) — injectables produce higher peak testosterone levels than gels or patches, driving stronger EPO stimulation
• Higher doses — more testosterone generally means more red blood cell production
• Less frequent injections — biweekly injections create larger peaks than weekly or twice-weekly dosing
• Untreated sleep apnea — independently raises EPO production by lowering blood oxygen during sleep; combined with TRT the effect compounds significantly
• Smoking — reduces blood oxygen saturation, triggering compensatory RBC production
• High altitude residence — similar mechanism to smoking
• Older age and higher baseline hematocrit — men starting TRT with hematocrit already at the high end of normal are at greater risk
• Chronic dehydration — concentrates existing red blood cells and can push borderline hematocrit into concerning range

Men with multiple risk factors — for example, an older man on biweekly injections with undiagnosed sleep apnea — are at the highest risk for rapid hematocrit elevation. Identifying these factors before starting TRT allows your physician to choose a delivery method and monitoring schedule that minimizes risk from the outset.

Understanding the Numbers: What Your Hematocrit Means

Hematocrit is the most practical marker for monitoring red blood cell levels on TRT. Here is how physicians interpret it:

• Under 50% — Normal range for adult men. No action required beyond continued routine monitoring.
• 50–54% — Elevated. Warrants close monitoring, lifestyle review (hydration, sleep apnea evaluation), and often a protocol adjustment at the next visit.
• Above 54% — Clinically significant erythrocytosis. Active management required. Most clinical guidelines recommend pausing TRT until levels normalize before restarting on a modified protocol.
• Above 58–60% — Requires urgent evaluation. Therapeutic phlebotomy is typically indicated immediately.

Your physician will review hemoglobin and total red blood cell count alongside hematocrit. Blood viscosity — the property that drives most cardiovascular risk — increases sharply above a hematocrit of 54%, which is why that threshold functions as the primary clinical action point in TRT management guidelines.

The Real Risks: Why Elevated Hematocrit Matters

The central concern with elevated hematocrit is hyperviscosity — blood that is too thick to flow efficiently through vessels. Consequences of untreated, sustained erythrocytosis can include:

• Deep vein thrombosis (DVT) — clot formation in leg veins, often painful and potentially life-threatening if the clot migrates
• Pulmonary embolism — a DVT clot traveling to the lungs, a medical emergency
• Stroke — sluggish blood flow in cerebral vessels increases the likelihood of clot formation
• Heart attack — thicker blood is harder for the heart to pump and clots more readily in coronary arteries
• Hypertension — increased blood viscosity raises vascular resistance, elevating blood pressure
• Headaches and cognitive sluggishness — early symptoms of hyperviscosity that some men report before lab abnormalities become severe

It is critical to put this in context: the serious cardiovascular outcomes above are primarily seen in men with sustained, unmonitored erythrocytosis. Men on well-managed TRT protocols who receive regular labs and protocol adjustments are almost never at serious risk, because intervention happens well before dangerous thresholds are reached. The risk is real — but so is the solution.

Management Strategies: How Lite Medical Handles Elevated Hematocrit

At Lite Medical, monitoring and management of hematocrit is built into every TRT protocol. Here is how our physicians approach it at each stage:

Baseline and Follow-Up Lab Monitoring

Before starting TRT, a complete blood count (CBC) is ordered to establish your baseline hematocrit. Follow-up labs are ordered at 6 weeks, and 3 months for new patients, and , and then every 6-8 months for stable patients. If hematocrit is trending upward or protocol changes are made, labs are ordered more frequently to stay ahead of the curve.

Delivery Method and Dose Adjustment

When hematocrit is rising but still below 54%, the first intervention is usually a protocol modification rather than stopping treatment:

• Reduce the total weekly testosterone dose — even a modest reduction can meaningfully blunt EPO stimulation
• Increase injection frequency — splitting a weekly dose into twice-weekly injections reduces peak testosterone levels, which is the primary driver of erythrocytosis
• Switch from intramuscular to subcutaneous injection — subcutaneous delivery produces lower, more stable testosterone levels.  We do not recommend IM injections of testosterone for any of our TRT patients.
• Transition to transdermal delivery (gel or cream) — generally associated with lower erythrocytosis rates because peaks are blunted compared to injections

Therapeutic Phlebotomy

When hematocrit exceeds 54% or fails to respond adequately to protocol adjustments, therapeutic phlebotomy is the fastest and most effective intervention. A phlebotomy removes approximately 450–500 mL of whole blood, which directly reduces red blood cell volume and typically drops hematocrit by 3–4 percentage points within days.

Therapeutic phlebotomy is safe, simple, and well-tolerated by most men. Many physicians recommend blood donation at a local blood bank as a practical alternative — it accomplishes the same reduction in red cell volume and benefits someone else at the same time. (Some donation centers ask about medications; disclose your TRT if asked, as eligibility policies vary.)

Hydration

Dehydration concentrates red blood cells and artificially elevates hematocrit readings without an actual increase in RBC production. Adequate daily fluid intake — at least 2–3 liters for most active men — is an easy, zero-risk intervention that can keep borderline values from tipping over threshold. This is especially important during Minnesota summers or for men who exercise heavily or work physical jobs.

Treating Underlying Contributors

Untreated sleep apnea is one of the strongest independent drivers of erythrocytosis outside of TRT itself. If hematocrit is rising despite dose adjustments, your physician will evaluate for sleep apnea and recommend a sleep study if indicated. Treating apnea with CPAP frequently reduces hematocrit meaningfully — often enough to allow continuation of TRT at a therapeutic dose without further intervention.

Temporary TRT Hold

In cases where hematocrit rises above 54% and does not respond quickly to the measures above, your physician may recommend a temporary pause in TRT for 4–8 weeks to allow hematocrit to normalize before restarting at a modified protocol. This is a reset, not a permanent discontinuation — the goal is to safely re-establish testosterone therapy at a dose and delivery method that keeps labs in range.  At Lite, we are sometimes able to continue modified therapy if the patient is able to donate blood (therapeutic phlebotomy) in a timely manner.

When to Rule Out Other Causes

In rare cases, markedly elevated hematocrit may not be driven solely by TRT. Polycythemia vera — a bone marrow disorder that causes independent overproduction of red blood cells — must be ruled out if values are very high (above 60%), if spleen enlargement or unusual symptoms are present, or if hematocrit remains elevated after TRT is paused. Your physician will determine whether hematology referral is appropriate based on your full clinical picture.

The Bottom Line for Minnesota Men on TRT

Erythrocytosis is the most common lab abnormality in TRT patients — and it is also one of the most manageable. With consistent monitoring and a physician who adjusts protocols based on labs, the vast majority of men on testosterone therapy never experience hematocrit-related complications.

At Lite Medical, hematocrit monitoring is not optional — it is built into every TRT protocol. Every patient receives regular CBC monitoring, and protocol adjustments happen proactively, not reactively. That is what physician-managed testosterone therapy looks like.

If you are currently on TRT through another provider and do not know what your hematocrit is, that is a gap worth closing. If you are considering TRT and want to understand how Lite Medical approaches it safely, schedule a Premier Discovery Intake to speak directly with one of our physicians.